VIA
ACHN

Vantage Investment Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Vantage Investment Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-500
Closed -$5K – 808
2015
Q1 		$5K Sell
500
-500
-50% -$6.24K ﹤0.01% 697
2014
Q4 		$12K Buy
+1,000
New +$12.2K 0.01% 471

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vantage Investment Advisors's ACHN Position: Q2 2015 in Review

Vantage Investment Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q2 2015, closing a stake of 500 shares — an estimated $5K sold.

Vantage Investment Advisors first reported a position in ACHN in Q4 2014 and held it in 2 quarters. The position peaked at $12K in Q4 2014. 158 funds tracked by Wall St. Rank hold ACHN as of Q2 2015.

  • Vantage Investment Advisors reported no remaining Achillion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Vantage Investment Advisors sold 500 Achillion Pharmaceuticals shares in Q2 2015, an estimated $5K.
  • Vantage Investment Advisors first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Vantage Investment Advisors's Achillion Pharmaceuticals position peaked at $12K in Q4 2014.
  • 158 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2015.

Based on Vantage Investment Advisors's 13F filing for Q2 2015, filed 5 Aug 2015.